Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Alongside its results, the company announced a significant product launch. On August 11, Pfizer rolled out its ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Pfizer launches PCV20 for adults in India to offer broad protection against pneumococcal disease: Our Bureau, Mumbai Wednesday, August 13, 2025, 15:45 Hrs [IST] Pfizer has announc ...

Pfizer has announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Pfizer's revenue grew 7.1% to ₹604 crore from ₹563 crore, while EBITDA increased 18.1% to ₹209.7 crore from ₹177.6 crore in ...